Back to portfolio

Anvesana is leveraging RNAseq analysis platform to treat rare genetic disorders caused by gene dosage effects.


Eric Ekland
President and Chief Executive Officer at Anvesana, Inc.

Partner in charge

Jaroslav Luptak


Anvesana is developing therapeutics to treat diseases caused by insufficient protein production. The core technology consists of an RNA-sequence analysis pipeline developed in the laboratory of Dr. Thomas Tuschl. Their platform can query mRNA sequence data to identify regions that can be targeted to up-regulate gene expression.